171 related articles for article (PubMed ID: 29804370)
21. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
Toso C; Meeberg GA; Bigam DL; Oberholzer J; Shapiro AM; Gutfreund K; Ma MM; Mason AL; Wong WW; Bain VG; Kneteman NM
Transplantation; 2007 May; 83(9):1162-8. PubMed ID: 17496530
[TBL] [Abstract][Full Text] [Related]
22. Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence.
Schnitzbauer AA; Schlitt HJ; Geissler EK
Transplantation; 2011 Jun; 91(11):1173-6. PubMed ID: 21427632
[TBL] [Abstract][Full Text] [Related]
23. Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital.
San Miguel C; Fundora Y; Triguero J; Muffak K; Villegas T; Becerra A; Garrote D; Ferrón JA
Transplant Proc; 2015 Oct; 47(8):2371-3. PubMed ID: 26518930
[TBL] [Abstract][Full Text] [Related]
24. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
[TBL] [Abstract][Full Text] [Related]
25. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
Kneteman NM; Oberholzer J; Al Saghier M; Meeberg GA; Blitz M; Ma MM; Wong WW; Gutfreund K; Mason AL; Jewell LD; Shapiro AM; Bain VG; Bigam DL
Liver Transpl; 2004 Oct; 10(10):1301-11. PubMed ID: 15376305
[TBL] [Abstract][Full Text] [Related]
26. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma.
Giakoustidis AE; Giakoustidis DE
Immunotherapy; 2017 Jan; 9(2):197-206. PubMed ID: 28128716
[TBL] [Abstract][Full Text] [Related]
27. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Geissler EK; Schnitzbauer AA; Zülke C; Lamby PE; Proneth A; Duvoux C; Burra P; Jauch KW; Rentsch M; Ganten TM; Schmidt J; Settmacher U; Heise M; Rossi G; Cillo U; Kneteman N; Adam R; van Hoek B; Bachellier P; Wolf P; Rostaing L; Bechstein WO; Rizell M; Powell J; Hidalgo E; Gugenheim J; Wolters H; Brockmann J; Roy A; Mutzbauer I; Schlitt A; Beckebaum S; Graeb C; Nadalin S; Valente U; Turrión VS; Jamieson N; Scholz T; Colledan M; Fändrich F; Becker T; Söderdahl G; Chazouillères O; Mäkisalo H; Pageaux GP; Steininger R; Soliman T; de Jong KP; Pirenne J; Margreiter R; Pratschke J; Pinna AD; Hauss J; Schreiber S; Strasser S; Klempnauer J; Troisi RI; Bhoori S; Lerut J; Bilbao I; Klein CG; Königsrainer A; Mirza DF; Otto G; Mazzaferro V; Neuhaus P; Schlitt HJ
Transplantation; 2016 Jan; 100(1):116-25. PubMed ID: 26555945
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppression and hepatocellular carcinoma.
Schlitt HJ; Mornex F; Shaked A; Trotter JF
Liver Transpl; 2011 Oct; 17 Suppl 2():S159-61. PubMed ID: 21506251
[No Abstract] [Full Text] [Related]
29. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators.
Zimmerman MA; Ghobrial RM; Tong MJ; Hiatt JR; Cameron AM; Hong J; Busuttil RW
Arch Surg; 2008 Feb; 143(2):182-8; discussion 188. PubMed ID: 18283144
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
31. [Orthotopic liver transplantation (first clinical experience)].
Konstantinov BA; Eramishantsev AK; Goté SV; Tsirulńikova OM; Skipenko OG; Lebezev VM; Shertsinger AG; Lokshin LS
Khirurgiia (Mosk); 1993 Mar; (3):32-44. PubMed ID: 8089967
[TBL] [Abstract][Full Text] [Related]
32. Immunosuppression does not enhance tumor growth after orthotopic liver transplantation for hepatoma.
Steininger R; Herbst F; Függer R; Mühlbacher F; Fritsch A
Transplant Proc; 1992 Dec; 24(6):2690-2. PubMed ID: 1334597
[No Abstract] [Full Text] [Related]
33. [Liver transplantation: personalized immunosuppression in patients with hepatitis C virus infection and hepatocellular carcinoma].
Rubín A; Berenguer M
Gastroenterol Hepatol; 2013 Jan; 36(1):48-57. PubMed ID: 22578313
[TBL] [Abstract][Full Text] [Related]
34. [Immunosuppression after liver transplant, now and in future].
Trunečka P
Vnitr Lek; 2013 Aug; 59(8):671-7. PubMed ID: 24007221
[TBL] [Abstract][Full Text] [Related]
35. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation.
Jiménez-Pérez M; González Grande R; Rando Muñoz FJ; de la Cruz Lombardo J; Muñoz Suárez MA; Fernández Aguilar JL; Pérez Daga JA; Santoyo-Santoyo J; Manteca González R; Rodrigo López JM
Transplant Proc; 2015; 47(1):90-2. PubMed ID: 25645779
[TBL] [Abstract][Full Text] [Related]
36. Effects of rapamycin in liver transplantation.
Chen YB; Sun YA; Gong JP
Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):25-8. PubMed ID: 18234634
[TBL] [Abstract][Full Text] [Related]
37. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression.
Vivarelli M; Cucchetti A; Piscaglia F; La Barba G; Bolondi L; Cavallari A; Pinna AD
Liver Transpl; 2005 May; 11(5):497-503. PubMed ID: 15838913
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center.
Hu AB; Wu LW; Tai Q; Zhu XF; He XS
J Dig Dis; 2013 Jan; 14(1):38-44. PubMed ID: 23134408
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of a Steroid-Free Immunosuppressive Regimen after Liver Transplantation for Hepatocellular Carcinoma.
Wei Q; Xu X; Wang C; Zhuang R; Zhuang L; Zhou L; Xie H; Wu J; Zhang M; Shen Y; Wang W; Zheng S
Gut Liver; 2016 Jul; 10(4):604-10. PubMed ID: 27074818
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
